[go: up one dir, main page]

MX2016004742A - DERIVATIVES OF PIRIDIL KETONE, METHOD OF PREPARATION OF THE SAME, AND THE PHARMACEUTICAL APPLICATION OF THE SAME. - Google Patents

DERIVATIVES OF PIRIDIL KETONE, METHOD OF PREPARATION OF THE SAME, AND THE PHARMACEUTICAL APPLICATION OF THE SAME.

Info

Publication number
MX2016004742A
MX2016004742A MX2016004742A MX2016004742A MX2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A
Authority
MX
Mexico
Prior art keywords
same
preparation
piridil
ketone
derivatives
Prior art date
Application number
MX2016004742A
Other languages
Spanish (es)
Other versions
MX377816B (en
Inventor
Tu Wangyang
Zhang Haitang
Xu Guoji
Chi Jiangtao
Original Assignee
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai hengrui pharmaceutical co ltd filed Critical Shanghai hengrui pharmaceutical co ltd
Publication of MX2016004742A publication Critical patent/MX2016004742A/en
Publication of MX377816B publication Critical patent/MX377816B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de cetona pirídicos, el método de preparación de los mismos, y la aplicación farmacéutica de los mismos. Específicamente la presente invención se refiere a derivados cetona pirídicos representados por la general (I) y las sales de los mismos, método de preparación de los mismos y usos de los mismos como inhibidores de MEK y especialmente como agentes terapéuticos para cáncer, donde las definiciones de los sustituyentes en la fórmula general (I) son las mismas como la definición en la descripción. (ver Fórmula).The present invention relates to pyridic ketone derivatives, the method of preparation thereof, and the pharmaceutical application thereof. Specifically, the present invention relates to pyridic ketone derivatives represented by general (I) and salts thereof, method of preparation thereof and uses thereof as MEK inhibitors and especially as therapeutic agents for cancer, where definitions of the substituents in the general formula (I) are the same as the definition in the description. (see Formula).

MX2016004742A 2013-10-25 2014-09-05 PYRIDIL KETONE DERIVATIVES, METHOD OF PREPARING THE SAME, AND THEIR PHARMACEUTICAL APPLICATION. MX377816B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310512377 2013-10-25
PCT/CN2014/085976 WO2015058589A1 (en) 2013-10-25 2014-09-05 Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof

Publications (2)

Publication Number Publication Date
MX2016004742A true MX2016004742A (en) 2016-12-09
MX377816B MX377816B (en) 2025-03-11

Family

ID=52992223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004742A MX377816B (en) 2013-10-25 2014-09-05 PYRIDIL KETONE DERIVATIVES, METHOD OF PREPARING THE SAME, AND THEIR PHARMACEUTICAL APPLICATION.

Country Status (15)

Country Link
US (2) US9914703B2 (en)
EP (1) EP3061747B1 (en)
JP (1) JP6403172B2 (en)
KR (1) KR102222569B1 (en)
CN (1) CN104936945B (en)
AU (1) AU2014339527B2 (en)
BR (1) BR112016007396B1 (en)
CA (1) CA2927635C (en)
ES (1) ES2868450T3 (en)
MX (1) MX377816B (en)
PL (1) PL3061747T3 (en)
PT (1) PT3061747T (en)
RU (1) RU2667892C2 (en)
TW (1) TWI662026B (en)
WO (1) WO2015058589A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118911B2 (en) * 2015-03-27 2018-11-06 Jiangsu Hengrui Medicine Co., Ltd. P-toluenesulfonate for MEK kinase inhibitor, and crystal form thereof and preparation method therefor
CN104892499B (en) * 2015-06-26 2017-07-21 江西省科学院应用化学研究所 A kind of synthetic method of 2 pyridinone derivatives
WO2018095403A1 (en) * 2016-11-25 2018-05-31 江苏恒瑞医药股份有限公司 Pyridone derivative pharmaceutical composition and preparation method thereof
TW201821408A (en) * 2016-12-01 2018-06-16 大陸商江蘇恆瑞醫藥股份有限公司 Preparation method for pyridic ketone derivatives and intermediate thereof
CN108314645A (en) * 2017-01-18 2018-07-24 上海映诺济生物科技有限公司 One kind has compound, preparation method and the purposes of antiproliferation
AU2018289864B2 (en) 2017-06-23 2022-03-31 Cstone Pharmaceuticals Coumarin-like cyclic compound as MEK inhibitor and use thereof
CN112912380B (en) * 2018-12-21 2023-08-11 基石药业（苏州）有限公司 Crystal form and amorphous form of MEK inhibitor and application thereof
WO2020156162A1 (en) * 2019-01-29 2020-08-06 贝达药业股份有限公司 Mek inhibitor and pharmaceutical use thereof
CN111514140B (en) * 2019-02-01 2021-09-03 江苏恒瑞医药股份有限公司 Application of MEK inhibitor and androgen receptor antagonist in preparation of tumor treatment drug
JP2022526713A (en) 2019-03-21 2022-05-26 オンクセオ Dbait molecule in combination with a kinase inhibitor for the treatment of cancer
TW202114994A (en) * 2019-07-29 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 Preparation method of 1,6-dihydropyridine-3-formamide derivative
TW202114667A (en) * 2019-09-11 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Use of combination of mek inhibitor and cdk4/6 inhibitor in preparing medicine for treating tumor
KR20220098759A (en) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) A method of treating cancer that has acquired resistance to a kinase inhibitor
AR121078A1 (en) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd ARILAMIDE DERIVATIVES WITH ANTI-TUMOR ACTIVITY
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111848613B (en) * 2020-08-11 2021-09-24 山东大学 A kind of diarylpyrimidine pyridone derivatives and preparation method and application thereof
JP7530596B2 (en) * 2021-04-14 2024-08-08 塩野義製薬株式会社 Triazine derivatives having an inhibitory effect on viral proliferation and pharmaceutical compositions containing the same
CN114605408B (en) * 2022-03-30 2023-06-16 沈阳药科大学 5-hydroxy-1, 3-disubstituted phenylpyrido [2,3-d ] pyrimidine compound and preparation method and application thereof
TW202404581A (en) * 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek inhibitors and uses thereof
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN120441478A (en) * 2024-02-07 2025-08-08 成都赜灵生物医药科技有限公司 A six-membered lactam compound and its application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005969A2 (en) * 2001-07-12 2003-01-23 Bristol-Myers Squibb Pharma Company Tetrahydropurinones as corticotropin releasing factor
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
PL1761528T3 (en) 2004-06-11 2008-05-30 Japan Tobacco Inc 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
NZ563707A (en) * 2005-05-18 2011-01-28 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
CN101389609B (en) * 2006-02-22 2012-01-11 霍夫曼-拉罗奇有限公司 Hydantoin-based kinase inhibitors
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
CA2727252A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
CN102134218A (en) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-aryl amino pyridone sulfamide and 6-aryl amino pymetrozine sulfamide methyl ethyl ketone (MEK) inihibitor
US20120238599A1 (en) * 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
US20140228418A1 (en) * 2011-05-23 2014-08-14 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
JP6431770B2 (en) * 2012-03-14 2018-11-28 ルピン・リミテッド Heterocyclyl compounds as MEK inhibitors

Also Published As

Publication number Publication date
MX377816B (en) 2025-03-11
TW201518278A (en) 2015-05-16
CA2927635C (en) 2021-07-20
US9914703B2 (en) 2018-03-13
CN104936945A (en) 2015-09-23
RU2667892C2 (en) 2018-09-25
JP2016534027A (en) 2016-11-04
US10064848B2 (en) 2018-09-04
KR102222569B1 (en) 2021-03-05
HK1212980A1 (en) 2016-06-24
JP6403172B2 (en) 2018-10-10
EP3061747A1 (en) 2016-08-31
EP3061747B1 (en) 2021-04-07
EP3061747A4 (en) 2017-05-10
KR20160074554A (en) 2016-06-28
US20160244410A1 (en) 2016-08-25
RU2016118753A (en) 2017-11-29
ES2868450T3 (en) 2021-10-21
WO2015058589A1 (en) 2015-04-30
PL3061747T3 (en) 2021-07-19
BR112016007396B1 (en) 2021-01-19
BR112016007396A2 (en) 2017-08-01
CN104936945B (en) 2017-11-03
CA2927635A1 (en) 2015-04-30
AU2014339527B2 (en) 2018-07-19
AU2014339527A1 (en) 2016-05-12
US20180016236A1 (en) 2018-01-18
TWI662026B (en) 2019-06-11
PT3061747T (en) 2021-05-04
RU2016118753A3 (en) 2018-05-25

Similar Documents

Publication Publication Date Title
MX2016004742A (en) DERIVATIVES OF PIRIDIL KETONE, METHOD OF PREPARATION OF THE SAME, AND THE PHARMACEUTICAL APPLICATION OF THE SAME.
ECSP20033467A (en) MACROCYCLIC COMPOUNDS TO TREAT DISEASES
MX2023001876A (en) Rapamycin derivatives.
CL2018003681A1 (en) Boronic acid derivatives and therapeutic uses thereof
DOP2015000241A (en) BIARIL-AMIDA COMPOUNDS AS CINASA INHIBITORS
CR20150472A (en) USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERS
CU20180152A7 (en) PYRIMIDIN-2-ILAMINO-1H-PYRAZOLES USEFUL AS LRRK2 INHIBITORS
DOP2014000204A (en) HETEROCICLYL COMPOUNDS AS MEK INHIBITORS
UY35663A (en) DERIVATIVES OF PIPERIDINIL-INDOL AS INHIBITORS OF COMPLEMENT FACTOR B AND USES OF THE SAME
MX2016014547A (en) Compounds for treating spinal muscular atrophy.
GT201400290A (en) FUNGICIDE HETEROCICLIC CARBOXAMIDS
GT201400178A (en) OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF THE PI3KS
ECSP15045801A (en) 6-(5-HYDROXY-1H-PYRAZOLE-1-IL)NICOTINAMIDE PHD INHIBITORS
ECSP14013215A (en) NEW COMPOUNDS
CR20160072A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE MEK
UY35551A (en) HETEROARILE DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
MX2016005142A (en) DERIVATIVES OF PIRAZOLOPIRIMIDONA OR PIRROLOTRIAZONA, METHOD AND PREPARATION OF THE SAME AND PHARMACEUTICAL APPLICATIONS OF THE SAME.
CO2017003955A2 (en) 1-Alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and uses thereof
CO7350640A2 (en) Dimeric compounds
MX2015009479A (en) COMPOUNDS AND METHODS TO TREAT BACTERIAL INFECTIONS.
DOP2018000062A (en) PIRIDINONA DICABOXAMIDS FOR USE AS BROMODOMINUM INHIBITORS
MX2016012784A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions.
CO2017000011A2 (en) Quinolizinone derivatives as pi3k inhibitors
UY36228A (en) HETEROARILO DERIVATIVES AS INHIBITORS OF ALDOSTERONE SINTASA (CYP11B2) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR132461A2 (en) Piperidinyl-indole derivatives as complement factor B inhibitors and their uses